1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Amneal Is Targeting 70% Of Untapped Biologics In The ‘Golden Era’ Of Biosimilars

As The Firm Prepares For First Generic Rivals For Its Innovative Parkinson’s Drug Rytary

 
• By Urtė Fultinavičiūtė

While Amneal cannot wait to jump into unexplored biologics space, it wants to channel its GLP-1 power into the Metsera partnership and service big pharma, and less so on its own generics.

A vault full of gold bars
(Shutterstock)

“It is our cup of tea,” is how Amneal’s co-CEO Chirag Patel described the firm’s passion for biosimilars at the recent J.P. Morgan Healthcare Conference.

The firm has previously acknowledged the integration of biosimilars as a key business development priority in 2025. Patel shared...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Business